New Cancer Immunotherapy Agents in Development
November 9, 2016
Gaylord National Hotel & Convention Center
Adrian Bot, MD, PhD – Kite Pharma, Inc.
Daniel S. Chen, MD, PhD – Genentech
Roger D. Dansey, MD – Merck & Co., Inc.
Ramy Ibrahim, MD♦ – The Parker Institute for Cancer Immunotherapy
Salil Patel, PhD – Bristol-Myers Squibb
Organized in collaboration with the SITC Annual Program Committee and SITC Industry Committee, this program consisted of rapid-fire presentations on cutting-edge new cancer immunotherapy agents in development and an extended panel session discussing strategic considerations of combinations and biomarkers in current and future agents.
The intended audience for this program included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; clinicians; and payers involved in cancer research from such affiliations as academia, industry and regulatory agencies.
Upon completion of this meeting, participants are now able to:
- Analyze cancer immunotherapy agents currently in development by identifying their target molecules and mechanisms of action
- Discuss strategic considerations of combinations and biomarkers in the development of new cancer immunotherapies
- Identify molecules beyond PD-1, PD-L1, and CTLA-4 that are being targeted in new cancer immunotherapy agents
The New Cancer Immunotherapy Agents in Development was supported in part by grants from AstraZeneca and Kite Pharma, Inc.